EUCTR2012-002839-28-GB进行中（未招募）1 期
A long-term, randomised, double-blind, placebo-controlled, multinational, multi-centre trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes - SUSTAIN™ 6 – Long term outcomes
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 3,297
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •- Men and women with type 2 diabetes mellitus.
- •- Age =50 years at screening and clinical evidence of cardiovascular disease or age =60 years at screening and subclinical evidence of cardiovascular disease.
- •- Anti-diabetic drug naïve, or treated with one or two OAD(s), or treated with human NPH insulin or long-acting insulin analogue or pre-mixed insulin, both types of insulin either alone or in combination with one or two OAD(s).
- •- HbA1c =7.0% at screening.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1630
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1630
排除标准
- •- Type 1 diabetes mellitus.
- •- Use of GLP-1 receptor agonist (exenatide, liraglutide, or other) or pramlintide within 90 days prior to screening.
- •- Use of any DPP-IV inhibitor within 30 days prior to screening.
- •- Treatment with insulin other than basal and pre-mixed insulin within 90 days prior to screening - except for short-term use in connection with intercurrent illness.
- •- Acute decompensation of glycaemic control requiring immediate intensification of treatment to prevent acute complications of diabetes (eg diabetes ketoacidosis) within 90 days prior to screening.
- •- History of chronic pancreatitis or idiopathic acute pancreatitis.
- •- Acute coronary or cerebro-vascular event within 90 days prior to randomisation.
- •- Currently planned coronary, carotid or peripheral artery revascularisation.
- •- Chronic heart failure NYHA class IV.
- •- Personal or family history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma.
- •- Personal history of non-familial medullary thyroid carcinoma.
- •- Screening calcitonin =50 ng/L.
研究者
相似试验
进行中（未招募）
1 期
A study of mepolizumab (study medicine) as an add-on therapy in subjects with severe uncontrolled asthmaSubjects with severe asthmaMedDRA version: 17.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2014-002513-27-ITGlaxoSmithKline Research & Development Ltd544
进行中（未招募）
1 期
A test in female patients with breast cancer to probably reduce side effects on blood cells by the planned chemotherapy and to collect data for medical research and drug development on the safety, possible benefits and distribution of an experimental drug called Myelo001 in comparison to a standard treatment.Chemotherapy-induced neutropenia (CIN)MedDRA version: 20.0Level: PTClassification code 10072806Term: Chemotherapy toxicity attenuationSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2015-003610-25-DEMyelo Therapeutics GmbH130
进行中（未招募）
不适用
Efficacy and safety of 2 doses of Tiotropium Respimat compared to placebo in adolescents with severe persistent asthmapatients of either sex, 12 to 17 years old, with a diagnosis of severe persistent asthmaMedDRA version: 16.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-021778-13-BGBoehringer Ingelheim RCV Gmb & Co KG375
进行中（未招募）
不适用
Efficacy and safety of tiotropium inhalation solution via Respimat® inhaler over 12 weeks on top of usual care in children (6 to 11 years old) with severe persistent asthmaSevere persistent asthmaMedDRA version: 18.0Level: LLTClassification code 10003560Term: Asthma NOSSystem Organ Class: 100000004855EUCTR2011-001777-43-PLBoehringer375
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of ropinirole for 26 weeks and to further evaluate the incidence of augmentation and rebound for a further 40 weeks open-label extension treatment period in subjects suffering from moderate to severe Restless Legs SyndromeRestless Legs Syndrome (RLS)EUCTR2005-005372-32-PTGlaxoSmithKline Research & Development Ltd400